Literature DB >> 15175800

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.

Sebastian Harder1, Jochen Graff, Ute Klinkhardt, Nils von Hentig, Jeanine M Walenga, Hikari Watanabe, Masanori Osakabe, Hans-Klaus Breddin.   

Abstract

Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, pro-thrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT, INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 microg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INR(ARG+VKA) = intercept + slope * INR (VKA alone)) was observed between the INR measured "on" and "off" ARG. The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR (ARG+VKA) and INR (VKA alone)) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13. There was a close correlation between plasma levels of ARG and aPTT or ECT. Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG, VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 microg/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175800     DOI: 10.1160/TH03-12-0794

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

1.  Comparison of two different ecarin clotting time methods.

Authors:  Tivadar Fenyvesi; Job Harenberg; Christel Weiss; Ingrid Jörg
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

2.  A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants.

Authors:  Sascha Meyer Dos Santos; Anita Zorn; Zeno Guttenberg; Bettina Picard-Willems; Christina Kläffling; Karen Nelson; Ute Klinkhardt; Sebastian Harder
Journal:  Biomicrofluidics       Date:  2013-10-04       Impact factor: 2.800

Review 3.  Direct thrombin inhibitors: pharmacology and application in intensive care medicine.

Authors:  Eva Schaden; Sibylle A Kozek-Langenecker
Journal:  Intensive Care Med       Date:  2010-04-28       Impact factor: 17.440

Review 4.  Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations.

Authors:  Sebastian Harder; Ute Klinkhardt; John M Alvarez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Heparin-induced thrombocytopenia: present and future.

Authors:  Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

6.  Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.

Authors:  John R Bartholomew; Carolynn E Pietrangeli; Marcie J Hursting
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  [Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia].

Authors:  S A Kozek-Langenecker
Journal:  Anaesthesist       Date:  2008-06       Impact factor: 1.041

8.  [Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient: therapy management using the direct thrombin inhibitor argatroban].

Authors:  S Heil
Journal:  Anaesthesist       Date:  2009-11       Impact factor: 1.041

Review 9.  Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.

Authors:  Marcie J Hursting; Joseph Soffer
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT.

Authors:  Andreas Koster; Karl-Georg Fischer; Sebastian Harder; Fritz Mertzlufft
Journal:  Biologics       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.